Luis Meza Contreras, MD
Hospital ResidentCards
About
Research
Publications
2024
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, Frankel P, Llamas-Quitiquit M, Hsu J, Zengin Z, Alcantara M, Castro D, Mercier B, Chawla N, Chehrazi-Raffle A, Barragan-Carrillo R, Jaime-Casas S, Govindarajan A, Gillece J, Trent J, Lee P, Parks T, Takahashi M, Hayashi A, Kortylewski M, Caporaso J, Lee K, Tripathi A, Pal S. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine 2024, 1-10. PMID: 38942995, DOI: 10.1038/s41591-024-03086-4.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalRenal cell carcinomaCell carcinomaToxicity profileAbundance of Bifidobacterium sppControl armTreatment-naive participantsFirst-line treatmentPhase 1 studyPhase 1 trialSarcomatoid componentOpen-labelHistological confirmationPrimary endpointSecondary endpointsNo significant differenceClear cellNivolumabInvestigator-initiatedClinical outcomesCabozantinibClinical activityStool samplesStudy armsImpact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC).
Dizman N, Ebrahimi H, Barragán Carrillo R, Meza L, Bergerot P, Dorff T, Hsu J, Zengin Z, Castro D, Chehrazi-Raffle A, Tripathi A, Trent J, Takahashi M, Oka K, Higashi S, Caporaso G, Lee K, Pal S. Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2024, 42: 4550-4550. DOI: 10.1200/jco.2024.42.16_suppl.4550.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsStandard of careStandard of care cohortGut microbiome compositionMicrobiome compositionClinical outcomesCell metastatic renal cell carcinomaRandomized phase I clinical trialGut dysbiosisAssociated with ICI responseStandard of care regimensClinically relevant microbial speciesCompared gut microbiome diversityPhase I clinical trialClinically relevant speciesPhase III studyRelevant microbial speciesBaseline to weekFirst-line treatmentGut microbiome diversityRatio of Firmicutes/BacteroidetesRenal cell carcinomaWilcoxon matched pairs testAnalyzed stool samplesImpact of Latino ethnicity on the gut microbiome composition of patients with metastatic renal cell cancer (mRCC).
Barragán Carrillo R, Dizman N, Ebrahimi H, Meza L, Bergerot P, Dorff T, Hsu J, Zengin Z, Salgia N, Chehrazi-Raffle A, Tripathi A, Castro D, Mercier B, Caporaso G, Lee K, Pal S. Impact of Latino ethnicity on the gut microbiome composition of patients with metastatic renal cell cancer (mRCC). Journal Of Clinical Oncology 2024, 42: 4521-4521. DOI: 10.1200/jco.2024.42.16_suppl.4521.Peer-Reviewed Original ResearchMetastatic renal cell cancerImmune checkpoint inhibitionGut microbiome compositionBeta diversityBacterial speciesANCOM-BCAbundance of bacterial speciesWhole metagenome sequencingF/B ratioRatio of Firmicutes/BacteroidetesStool specimensShannon diversity indexR. inulinivoransE. rectaleRenal cell cancerTaxonomic profilesMetagenomic sequencingAlpha diversityGut microbiotaGut microbiomeMicrobiome compositionBray-CurtisDiversity indexComposition of patientsGut dysbiosisPrevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy
Ebrahimi H, Battle D, Salgia N, Zengin Z, Dizman N, Meza L, Bergerot C, Barragan-Carrillo R, Hsu J, Castro D, Mercier B, Chawla N, Li X, Tripathi A, Liu S, Chehrazi-Raffle A, Vaishampayan U, Staehler M, Pal S. Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy. Nutrients 2024, 16: 1630. PMID: 38892563, PMCID: PMC11174627, DOI: 10.3390/nu16111630.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaCell carcinomaDietary modificationSupplement useDiagnosis of renal cell carcinomaFirst-line treatmentSupplement usageSystemic therapyCombination therapyAntineoplastic therapyKetogenic dietCarcinomaCancer therapyMediterranean dietPhysician-patient dialoguePatientsTherapyCancer treatmentGrowing body of evidenceBody of evidenceDietary changesCancerCancer diagnosisCannabidiolCD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Pal S, Tran B, Haanen J, Hurwitz M, Sacher A, Tannir N, Budde L, Harrison S, Klobuch S, Patel S, Meza L, Dequeant M, Ma A, He Q, Williams L, Keegan A, Gurary E, Dar H, Karnik S, Guo C, Heath H, Yuen R, Morrow P, Agarwal N, Srour S. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discovery 2024, 14: of1-of14. PMID: 38583184, PMCID: PMC11215406, DOI: 10.1158/2159-8290.cd-24-0102.Peer-Reviewed Original ResearchClear cell renal cell carcinomaChimeric antigen receptorCAR-T cellsT-cell therapyCell renal cell carcinomaRenal cell carcinomaT cellsCell carcinomaSolid tumorsAllogeneic CAR-T cell therapyChimeric antigen receptor T cellsAdvanced clear cell renal cell carcinomaAllogeneic CAR-T cellsClinical trialsCAR-T cell productsCAR-T cell therapyTreatment of solid tumorsFirst-in-human clinical trialCAR-T constructsDose-limiting toxicityT cell productionNovel treatment optionsTreatment of clear cell renal cell carcinomaHematologic malignanciesAntigen receptorImpact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations
Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan B, Pal S. Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations. European Urology Focus 2024 PMID: 38580524, DOI: 10.1016/j.euf.2024.03.006.Peer-Reviewed Original ResearchTime to treatment failureDisease control rateRenal cell carcinomaSynchronous metastasesMetachronous metastasesOverall survivalMetachronous metastatic renal cell carcinomaMedian time to treatment failureICI-based combination therapyAssociated with worse OSMetastatic renal cell carcinomaFirst-line immunotherapyICI-based combinationsRenal cell carcinoma diagnosisDiagnosis of kidney cancerHypothesis-generating studyMedian OSMetachronous groupPoor OSTreatment failureCombination therapyMetastasis onsetCell carcinomaSurvival outcomesClinical outcomesBarriers to Clinical Trial Implementation Among Community Care Centers
Ebrahimi H, Megally S, Plotkin E, Shivakumar L, Salgia N, Zengin Z, Meza L, Chawla N, Castro D, Dizman N, Bhagat R, Liv S, Li X, Rock A, Liu S, Tripathi A, Dorff T, Oyer R, Boehmer L, Pal S, Chehrazi-Raffle A. Barriers to Clinical Trial Implementation Among Community Care Centers. JAMA Network Open 2024, 7: e248739. PMID: 38683608, PMCID: PMC11059033, DOI: 10.1001/jamanetworkopen.2024.8739.Peer-Reviewed Original ResearchConceptsClinical trial implementationClinical trial enrollmentTrial enrollmentUnmet needsCancer clinical trial enrollmentHealth care practicesPatients seeking careTrial implementationCommunity care centersCommunity oncology settingNational survey studyRural practiceClinical research opportunitiesCare practicesCare settingsCancer clinicOncology settingLimited staffingPractice changeRural settingsOncology clinicMain OutcomesHispanic residentsReferral practicesTrial participantsAssociation between thymectomy and incidence of renal cell carcinoma (RCC).
Barragan-Carrillo R, Ebrahimi H, Chawla N, Salgia N, Castro D, Chehrazi-Raffle A, Dizman N, Hsu J, Meza L, Zengin Z, LeVee A, Tripathi A, Dorff T, Bergerot C, Bergerot P, Eilber K, Dallas K, Pal S. Association between thymectomy and incidence of renal cell carcinoma (RCC). Journal Of Clinical Oncology 2024, 42: 371-371. DOI: 10.1200/jco.2024.42.4_suppl.371.Peer-Reviewed Original ResearchRenal cell carcinomaIncidence of nephrectomyIncidence of renal cell carcinomaMedian age of patientsFrequency of nephrectomyAge of patientsT cell productionProportion of patientsRate of nephrectomyFisher's exact testGeneral populationAge-matched populationICD-9/10 codesPopulation-based cohortPopulation-based studyImmunogenic cancerPrior thymectomyChi-square testCell carcinomaMedian ageSurgical interventionNephrectomyThymectomyExact testOSHPD databaseEvolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial.
Ebrahimi H, Meza L, Lee K, Malhotra J, Alcantara M, Zengin Z, Dizman N, Hsu J, Llamas-Quitiquit M, Castro D, Mercier B, Barragan-Carrillo R, Chawla N, Li X, Liu S, Chehrazi-Raffle A, Dorff T, Frankel P, Tripathi A, Pal S. Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial. Journal Of Clinical Oncology 2024, 42: 460-460. DOI: 10.1200/jco.2024.42.4_suppl.460.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMetabolic pathwaysClinical outcomesAnnotated open reading framesFunction of microbial communitiesMetatranscriptomic sequencing dataWhole metagenome sequencingOpen reading frameGut microbial functionsGut microbiome functionsResponse rate to sorafenibExperimental armElectron transfer chainCancer cell typesAssociated with clinical outcomesRenal cell carcinomaReading frameSequence dataTaxonomic profilesBiosynthesis pathwayMetagenomic sequencingMicrobiome functionMicrobial functionsMolecular functionsRandomized clinical trialsImpact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).
Mercier B, Tripathi N, Govindarajan A, Gebrael G, Narang A, Li X, Castro D, Chehrazi-Raffle A, Dizman N, Ebrahimi H, Chawla N, Hsu J, Bergerot C, Barragan-Carrillo R, Zengin Z, Meza L, Pal S, Agarwal N, Tripathi A. Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC). Journal Of Clinical Oncology 2024, 42: 547-547. DOI: 10.1200/jco.2024.42.4_suppl.547.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaOverall survivalCox proportional hazards multivariate modelPresence of visceral metastasesChi-square test/Fisher's exact testIS groupPractice patternsPredictors of OSKaplan-Meier methodImpact practice patternsLog-rank testMedicare groupPrivate insuranceMulti-institutional studyANOVA/Kruskal-Wallis testVisceral metastasesInsurance payer statusNeoadjuvant chemotherapyNCI-designated comprehensive cancer centerSystemic therapyUrothelial carcinomaMedian ageBaseline characteristicsExact testClinical trial participation